Peter Goodwin and Sara Freeman interview conference speakers in Berlin regarding lapatinib's apparent effect on breast cancer "stem cells"; the lack of additional benefit from adding capecitabine to standard neoadjuvant chemotherapy; evidence that MRI improves surgical planning for breast cancer; news that aromatase inhibitors do not add to cardiovascular risk when used in adjuvant therapy instead of tamoxifen; and (from a satellite symposium) an assessment of the role of nanoparticle albumin-bound paclitaxel in therapy for metastatic breast cancer.

Share